Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Apellis Pharmaceuticals Inc (NASDAQ: APLS) closed at $27.34 up 2.47% from its previous closing price of $26.68. In other words, the price has increased by $2.47 from its previous closing price. On the day, 2.25 million shares were traded. APLS stock price reached its highest trading level at $27.8 during the session, while it also had its lowest trading level at $26.68.
Ratios:
For a deeper understanding of Apellis Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.18 and its Current Ratio is at 5.08. In the meantime, Its Debt-to-Equity ratio is 1.80 whereas as Long-Term Debt/Eq ratio is at 1.77.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on October 25, 2024, initiated with a Sector Perform rating and assigned the stock a target price of $25.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 16 ’24 when Dunlop A. Sinclair sold 37,000 shares for $36.23 per share. The transaction valued at 1,340,597 led to the insider holds 100,000 shares of the business.
Chopas James George sold 192 shares of APLS for $6,952 on Sep 16 ’24. The VP/Chief Accounting Officer now owns 38,141 shares after completing the transaction at $36.21 per share. On Sep 16 ’24, another insider, Chopas James George, who serves as the Officer of the company, bought 192 shares for $36.21 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, APLS now has a Market Capitalization of 3329082368 and an Enterprise Value of 3435560448. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.29 while its Price-to-Book (P/B) ratio in mrq is 12.59. Its current Enterprise Value per Revenue stands at 5.464 whereas that against EBITDA is -11.036.
Stock Price History:
Over the past 52 weeks, APLS has reached a high of $73.80, while it has fallen to a 52-week low of $26.28. The 50-Day Moving Average of the stock is -17.11%, while the 200-Day Moving Average is calculated to be -40.20%.
Shares Statistics:
For the past three months, APLS has traded an average of 2.11M shares per day and 2196330 over the past ten days. A total of 119.56M shares are outstanding, with a floating share count of 100.98M. Insiders hold about 17.07% of the company’s shares, while institutions hold 94.04% stake in the company. Shares short for APLS as of 1728950400 were 21088064 with a Short Ratio of 9.99, compared to 1726185600 on 15284852. Therefore, it implies a Short% of Shares Outstanding of 21088064 and a Short% of Float of 23.91.
Earnings Estimates
The dynamic stock of Apellis Pharmaceuticals Inc (APLS) is currently attracting attention from 19.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.2, with high estimates of -$0.03 and low estimates of -$0.41.
Analysts are recommending an EPS of between -$1.12 and -$1.67 for the fiscal current year, implying an average EPS of -$1.34. EPS for the following year is -$0.07, with 18.0 analysts recommending between $1.15 and -$0.89.
Revenue Estimates
A total of 20 analysts believe the company’s revenue will be $200.13M this quarter.It ranges from a high estimate of $219.73M to a low estimate of $183.98M. As of the current estimate, Apellis Pharmaceuticals Inc’s year-ago sales were $110.4MFor the next quarter, 20 analysts are estimating revenue of $213.73M. There is a high estimate of $238.63M for the next quarter, whereas the lowest estimate is $187M.
A total of 20 analysts have provided revenue estimates for APLS’s current fiscal year. The highest revenue estimate was $830.36M, while the lowest revenue estimate was $749M, resulting in an average revenue estimate of $785.69M. In the same quarter a year ago, actual revenue was $396.59MBased on 20 analysts’ estimates, the company’s revenue will be $1.01B in the next fiscal year. The high estimate is $1.2B and the low estimate is $848.53M.
